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Lars Leksell first introduced the concept of ste-reotactic radiosurgery in 1951, when he treated a patient suffering from classic TN using a proto-
type-guiding device linked to a dental x-ray machine.14 
Patterns of pain-free response in 497 cases of classic 
trigeminal neuralgia treated with Gamma Knife surgery 
and followed up for least 1 year
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Object. The goal of this study was to establish whether clear patterns of initial pain freedom could be identified 
when treating patients with classic trigeminal neuralgia (TN) by using Gamma Knife surgery (GKS). The authors 
compared hypesthesia and pain recurrence rates to see if statistically significant differences could be found.
Methods. Between July 1992 and November 2010, 737 patients presenting with TN underwent GKS and pro-
spective evaluation at Timone University Hospital in Marseille, France. In this study the authors analyzed the cases 
of 497 of these patients, who participated in follow-up longer than 1 year, did not have megadolichobasilar artery– or 
multiple sclerosis–related TN, and underwent GKS only once; in other words, the focus was on cases of classic TN 
with a single radiosurgical treatment. Radiosurgery was performed with a Leksell Gamma Knife (model B, C, or Per-
fexion) using both MR and CT imaging targeting. A single 4-mm isocenter was positioned in the cisternal portion of 
the trigeminal nerve at a median distance of 7.8 mm (range 4.5–14 mm) anterior to the emergence of the nerve. A me-
dian maximum dose of 85 Gy (range 70–90 Gy) was delivered. Using empirical methods and assisted by a chart with 
clear cut-off periods of pain free distribution, the authors were able to divide patients who experienced freedom from 
pain into 3 separate groups: patients who became pain free within the first 48 hours post-GKS; those who became 
pain free between 48 hours and 30 days post-GKS; and those who became pain free more than 30 days after GKS.
Results. The median age in the 497 patients was 68.3 years (range 28.1–93.2 years). The median follow-up 
period was 43.75 months (range 12–174.41 months). Four hundred fifty-four patients (91.34%) were initially pain 
free within a median time of 10 days (range 1–459 days) after GKS. One hundred sixty-nine patients (37.2%) be-
came pain free within the first 48 hours (Group PF≤ 48 hours), 194 patients (42.8%) between posttreatment Day 3 and 
Day 30 (Group PF(> 48 hours, ≤ 30 days)), and 91 patients (20%) after 30 days post-GKS (Group PF> 30 days). Differences in 
postoperative hypesthesia were found: in Group PF≤ 48 hours 18 patients (13.7%) developed postoperative hypesthesia, 
compared with 30 patients (19%) in Group PF(> 48 hours, ≤ 30 days) and 22 patients (30.6%) in Group PF> 30 days (p = 0.014). 
One hundred fifty-seven patients (34.4%) who initially became free from pain experienced a recurrence of pain with 
a median delay of 24 months (range 0.62–150.06 months). There were no statistically significant differences between 
the patient groups with respect to pain recurrence: 66 patients (39%) in Group PF≤ 48 hours experienced pain recurrence, 
compared with 71 patients (36.6%) in Group PF(> 48 hours, ≤ 30 days) and 27 patients (29.7%) in Group PF> 30 days (p = 0.515). 
Conclusions. A substantial number of patients (169 cases, 37.2%) became pain free within the first 48 hours. 
The rate of hypesthesia was higher in patients who became pain free more than 30 days after GKS, with a statistically 
significant difference between patient groups (p = 0.014).
(http://thejns.org/doi/abs/10.3171/2012.8.GKS121015)
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Abbreviations used in this paper: BNI = Barrow Neurological 
Institute; GKS = Gamma Knife surgery; Group PF = pain-free 
group; MS = multiple sclerosis; TN = trigeminal neuralgia.
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The use of GKS in the treatment of TN became more 
and more frequent starting in the 1990s, and an increas-
ing number of articles confirming its safety and efficacy 
have appeared since 1996,1–4,6,10,13,16–21,24 in what we called 
a “revolution” in functional neurosurgery in our recent 
editorial.22
The mechanisms of action that could explain the ef-
fectiveness of GKS for TN remain unclear, even though 
we now have persuasive evidence that demyelination of 
trigeminal sensory fibers plays an important role.15 Sev-
eral animal studies have also been performed in attempts 
to clarify the pathophysiological aspects of postoperative 
GKS effects.12,27
As we pointed out in our editorial,22 the number of 
articles about the role of GKS in the armamentarium for 
treating TN is continually growing. Thus far, few of them 
discuss the mechanism of action and neuromodulator ef-
fect of this radiosurgical technique because in many as-
pects the radiobiology remains unclear.
Methods
Patient Population and Selection for Treatment
Between July 1992 and November 2010, 737 patients 
presenting with intractable TN were treated with GKS 
and followed up prospectively at the Timone University 
Hospital in Marseille, France. We accepted for treatment 
patients fulfilling the criteria of the International Head-
ache Society,7 which included long-standing pain refrac-
tory to pharmacological treatment with agents such as 
carbamazepine, phenytoin, baclofen, gabapentin, and so 
forth.
Four hundred ninety-seven patients with more than 
1 year of follow-up comprised the study group that we 
finally analyzed. We deliberately excluded from our study 
patients whose TN was related to a megadolichobasilar 
artery or MS, as well as those who underwent a second 
GKS treatment. We focused only on cases of classic TN 
in which there was only 1 radiosurgical procedure.
Radiosurgical Technique
During this 18-year study, various models of the 
Gamma Knife (Elekta AB) were used: models B, C, 4C, 
and Perfexion. After a local anesthetic agent had been 
applied, the Leksell model G stereotactic frame (Elekta) 
was affixed to the patient head. All 497 patients (100%) 
underwent stereotactic MR imaging and CT scanning so 
that we could identify the position of the trigeminal nerve. 
The MR imaging sequences that we used included T2-
weighted constructive interference in steady state without 
contrast and contrast-enhanced T1-weighted images. The 
CT routinely supplemented this imaging to correct any 
distortion errors on the MR images.
A single 4-mm isocenter was used for all 497 patients 
and was positioned in the cisternal portion of the trigemi-
nal nerve, at a median distance of 7.8 mm (range 4.5–14 
mm) from the nerve’s emergence from the brainstem.
Patients continued their medication unchanged for 1 
month after GKS and then were able to diminish their 
drug doses depending on the treatment’s efficacy. We 
normally saw these patients for a neurological examina-
tion, including an assessment of facial sensibility and mo-
tility and corneal reflex, at 3 months, 6 months, and 1 year 
post-GKS, and then yearly thereafter.
A team consisting of a neurosurgeon, radiation on-
cologist, and a medical physicist performed dose selec-
tion and planning.
Follow-Up and Assessment of Outcome
The director of Marseille-Mediterranean University 
and the ethical committee of Timone University Hospital 
approved our study. Follow-up information was obtained 
by direct clinical evaluation or telephone interview by the 
first author (C.T.), who was not involved in the selection 
of cases for treatment. 
We evaluated the probability of onset of sensory dis-
turbance and pain recurrence in patients who became 
pain free after GKS. We recorded and analyzed the pre- 
and post-GKS latency intervals, paying attention to date 
every event, the use of medication, the need for further 
surgical procedures, and so forth, as well as the time 
needed for every patient who became pain free to develop 
new or recurrent disorders, so that we could assess all 
available information accurately.
Pain was scored using the BNI pain scale,24 which 
uses the following grades: I, no trigeminal pain with 
no medication; II, occasional pain that does not require 
medication; IIIa, no pain with continued medication; IIIb, 
persistent pain controlled by medication; IV, some pain 
not adequately controlled by medication; and V, severe 
pain with no relief.
For hypesthesia we used the BNI facial hypesthe-
sia scale,24 which uses the following grades: I, no facial 
numbness; II, mild facial numbess but not bothersome; 
III, facial numbness that is somewhat bothersome; and 
IV, facial numbness that is very bothersome. For patients 
presenting with facial nerve sensory dysfunction, we in-
quired about their quality of life as it related to TN and 
whether this sensory problem bothered them. We also 
asked these patients whether they had mastication diffi-
culties.
Statistical Analysis
Data were recorded using Microsoft Excel 2000. 
All statistical analyses were performed using R software 
(version 2.12.0, R Foundation for Statistical Computing). 
The survival R package was used for survival analysis.
We first conducted a descriptive analysis of recorded 
data for all 497 patients. We then compared the character-
istics of all 3 groups, Analysis of variance was performed 
when conditions were verified; otherwise we performed 
the Kruskal-Wallis test. For qualitative variables, we per-
formed the chi-square test when valid or the Fisher test 
otherwise.
To evaluate outcomes such as hypesthesia and pain 
recurrence, the time-to-event was estimated using the 
Kaplan-Meier method. A bivariate analysis was then per-
formed to identify predictive factors among the collected 
variables. For qualitative variables, Kaplan-Meier curves 
were used to represent time-to-event graphically among 
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the different groups and were compared using the uni-
variate log-rank test. Proportionality of hazards was as-
sessed graphically by using log cumulative hazard plots. 
All tests were 2-sided and p values < 0.05 were 
judged to be significant.
Evaluating and Deciding Patterns of Pain Free
We tried to establish different patterns of pain-free 
responses. We used empirical tests to divide patients into 
different groups depending on the time that passed after 
GKS before they became pain free. We also made a chart 
showing the distribution of patients and clear cut-offs of 
freedom from pain (Fig. 1), with 2 major peaks, one at 2 
days (48 hours) and the other at 30 days. Other small or 
medium peaks could be seen, but the number of patients 
achieving them was half or less compared with the other 
2 peaks. That is why we finally chose 3 patient groups: 
patients who became pain free within the first 48 hours 
after GKS (Group PF≤ 48 hours); those who became pain 
free more than 48 hours after GKS but before or at 30 
days after the procedure (Group PF(> 48 hours, ≤ 30 days)); and 
those who became pain free more than 30 days after GKS 
(Group PF> 30 days). We tested the patients’ clinical parame-
ters and tried to establish whether the rates of hypesthesia 
and pain recurrence were higher in one group or another. 
and if these results were statistically significant.
Results
General Data
The median age of the 497 patients was 68.3 years 
(range 28.1–93.2 years). The median age in Group PF≤ 
48 hours was 68.3 years (range 33.1–90.8 years), compared 
with 68.5 years (range 28.8–93.2 years) in Group PF(> 
48 hours, ≤ 30 days) and 68.3 years (range 43.3–87.8 years) in 
Group PF> 30 days (p = 0.991).
The median time between the first appearance of 
TN and treatment in Group PF≤ 48 hours was 76.5 months 
(range 0.8–531 months), compared with 67.5 months 
(range 1–387.5 months) in Group PF(> 48 hours, ≤ 30 days) and 
71 months (range 5–529 months) in Group PF> 30 days (p = 
0.554).
The median follow-up period was 43.75 months 
(range 12–174.4 months).
Four hundred fifty-four patients (91.34%) initially be-
came pain free at a median time of 10 days (range 1–459 
days) after GKS. Of these, 169 (37.2%) became pain free 
within the first 48 hours (Group PF≤ 48 hours), compared 
with 194 (42.8%) who became pain free between Day 
3 and Day 30 (Group PF(> 48 hours, ≤ 30 days)) and 91 patients 
(20%) who became pain free after 30 days (Group PF> 
30 days). Table 1 shows initial freedom from pain as well 
as the development of hypesthesia and pain recurrence 
within the 3 groups.
We studied the clinical parameters in all 3 subpopu-
lations. The pre-GKS assessment showed no statistically 
significant differences (see Table 2) between the 3 groups 
regarding the side of the pain (p = 0.73), presence of bi-
lateral pain (p = 0.85), number of dermatomes involved 
in the pain (p = 0.41), presence of atypical (p = 0.805) or 
continuous (p = 0.201) pain, neurovascular conflict evi-
dent on preoperative MR images (p = 0.743), or the sex of 
the patients (p = 0.612).
The number and types of previous surgical interven-
tions were also assessed. A summary is shown in Table 
3. Whether the patient had undergone previous surgical 
treatment (p = 0.576), the number of preoperative GKS 
interventions (p = 0.611), and most types of previous in-
tervention—thermocoagulation on the same side (p = 
0.565), balloon microcompression (p = 0.982), microvas-
cular decompression (p = 0.999) and glycerol injection 
(p = 1)—were not statistically significant. Only previous 
contralateral thermocoagulation (p = 0.04) was statisti-
cally significant for patterns of pain freedom. 
Regarding preoperative hypesthesia, we found no 
statistically significant difference between the 3 pain-
free groups (p = 0.874), as seen in Table 4. Only 1 person 
had preoperative anesthesia dolorosa; that patient was in 
Group PF≤ 48 hours (p = 0.572).
TABLE 1: Initial freedom from pain in and development of 
hypesthesia and pain recurrence in the 3 patient groups*
No. of Patients (%) (total no. of 
patients = 454)
Variable Group 1 Group 2 Group 3 p Value
initially pain free 169 (37.2) 194 (42.8) 91 (20)
hypesthesia 0.014
 yes 18 (13.7) 30 (19) 22 (30.6)
 no 113 (86.3) 128 (81) 50 (69.4)
pain recurrence 0.515
 yes 59 (34.9) 71 (36.6) 27 (29.7)
 no 110 (65.1) 123 (63.4) 64 (70.3)
* Group 1 = Group PF≤ 48 hours; Group 2 = Group PF(> 48 hours, ≤ 30 days); Group 
3 = Group PF> 30 days.
Fig. 1. Graph depicting the distribution of pain-free intervals after 
radiosurgery in a population of 497 patients with classic TN and only 
1 GKS treatment. (Patients with megadolichobasilar artery– or MS-
related TN were not included in the study group.)
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Post-GKS Hypesthesia
Among all 497 patients, the hypesthesia rate at 5 
years was 20.4%; at 7 years the rate reached 21.1% and 
remained stable until 14 years post-GKS, with a median 
delay of onset of 12 months (range 1–65 months). 
Statistically significant differences (p = 0.014) be-
tween the 3 pain-free groups were identified for post-
GKS hypesthesia: postoperative sensory disturbances 
developed in 18 patients (13.7%) in Group PF≤ 48 hours, com-
pared with 30 patients (19%) in Group PF(> 48 hours, ≤ 30 days) 
and 22 patients (30.6%) in Group PF> 30 days. Table 5 shows 
these findings. When hypesthesia was classified as mild 
or severe (discreet or important, respectively), the p value 
was 0.823, and when it was assessed using the BNI scale, 
the p value was 0.598.
Until 1 year after GKS, the risk of hypesthesia was 
similar in the 3 groups, but afterward there was a strong 
risk of hypesthesia in Group PF> 30 days.
We conclude that the lowest hypesthesia rate was 
found in patients who became pain free earliest (Group 
PF≤ 48 hours, 13.7% of patients) and the highest hypesthe-
sia rate was found in patients who became pain free last 
(Group PF> 30 days, 30.6% of patients).
Figure 2 shows the probability of hypesthesia onset 
within the 3 subgroups.
Probability of Maintaining Pain Relief and Management of 
Pain Recurrence
One hundred fifty-seven patients (34.4%) who be-
came pain free after GKS experienced a recurrence of 
TN pain with a median delay of 24 months (range 0.62–
150.06 months).
There were no statistically significant differences in 
the pain recurrence rates between patient groups: 66 pa-
tients (39%) in Group PF≤ 48 hours, 71 patients (36.6%) in 
Group PF(> 48 hours, ≤ 30 days), and 27 (29.7%) patients in Group 
PF> 30 days experienced at least 1 recurrence of pain (p = 
0.515).
Whether patients underwent additional surgical inter-
vention (p = 0.619); if performed, the number of additional 
surgical procedures (p = 0.477); and the type of additional 
surgical intervention (p = 0.849 for thermocoagulation; p 
= 0.873 for balloon microcompression; p = 0.602 for mi-
crovascular decompression; and p = 1 for cortical stimula-
tion) were not found to be statistically significant. A sum-
mary of these findings is shown in Table 6.
Figure 3 shows the probability of maintaining pain 
relief in the 3 subgroups.
Evaluation of Outcome at the Last Follow-Up
At the last follow-up, our results showed no statisti-
TABLE 2: Preoperative assessment of the 3 patient groups regarding some clinical aspects and the neurovascular 
conflict seen on preoperative MR images
No. of Patients (%)
Variable Group 1 (169 patients) Group 2 (194 patients) Group 3 (91 patients) p Value
side of pain 0.73
 rt 94 (55.6) 102 (52.6) 52 (57.1)
 lt 75 (44.4) 92 (47.4) 39 (42.9)
bilat pain 0.85
 yes 7 (4.1) 6 (3.1) 4 (4.4)
 no 162 (95.9) 188 (96.9) 87 (95.6)
no. of territories of pain 0.41
 1 87 (51.5) 116 (59.8) 48 (52.7)
 2 71 (42) 63 (32.5) 37 (40.7)
 3 11 (6.5) 15 (7.7) 6 (6.6)
atypical pain 0.805
 yes 36 (21.3) 37 (19.1) 20 (22)
 no 133 (78.7) 157 (80.9) 71 (78)
continuous pain 0.201
 yes 42 (24.9) 34 (17.5) 17 (18.7)
 no 127 (75.1) 160 (82.5) 74 (81.3)
previous neurovascular 
  conflict seen on MRI
0.743
  yes 92 (54.4) 110 (56.7) 54 (59.3)
  no 77 (45.6) 84 (43.3) 37 (40.7)
sex of patient 0.612
 male 79 (46.7) 82 (42.3) 43 (47.3)
 female 90 (53.3) 112 (57.7) 48 (52.7)
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cally significant differences between the 3 subgroups (p 
= 0.874 for the BNI classification). Table 7 shows these 
results.
Discussion
Even if the role of GKS in the armamentarium for 
treating TN is now well established, the radiobiological 
mechanisms of action associated with the procedure re-
main poorly understood.
When we discuss clinical and histopathological 
chains of events we cannot separate the causes of TN, 
which can differ greatly from one case to another: com-
pression by an overlying artery or vein (thought to ac-
count for 80%–90% of cases9) with focal demyelination, 
close apposition of demyelinated axons, few residual 
oligodendrocytes, and no inflammatory cells;8 primary 
demyelinating disorders (MS) with demyelination ex-
tending along the proximal part of the trigeminal nerve 
root and, in some cases, to the junction with the periph-
eral nerve system, juxtaposed axons, and the presence of 
variable thinly myelinated fibers; masses in the posterior 
fossa, small infarcts or angiomas in the pons or medulla 
oblongata, prosthetic materials inserted during microvas-
cular decompression;5 bone compression of the nerve;23,25 
and idiopathic cases or, less frequently, familial TN.11 In 
the majority of cases, the cause of TN seems to be demy-
elination, especially present at the level of the trigeminal 
root entry zone.15
Few studies have been conducted to understand the 
mechanism of action that occurs when GKS is used as a 
tool for treatment.
TABLE 3: Previous surgical intervention
No. of Patients (%)
Variable
Group 1 
(169 patients)
Group 2 
(194 patients)
Group 3 
(91 patients) p Value
surgical treatment before GKS 0.576
 yes 61 (36.1) 60 (30.9) 31 (34.1)
 no 108 (63.9) 134 (69.1) 60 (65.9)
no. of surgeries before GKS 0.611
  0 108 (63.9) 134 (69.1) 60 (65.9)
  1 38 (22.5) 36 (18.6) 16 (17.6)
  2 15 (8.9) 12 (6.2) 11 (12.1)
 ≥3 8 (4.7) 12 (6.2) 4 (4.4)
previous thermocoagulation on same side 0.565
 yes 132 (78.1) 160 (82.5) 74 (81.3)
 no 37 (21.9) 34 (17.5) 17 (18.7)
previous contralateral thermocoagulation 0.045
 yes 4 (2.4) 194 (100) 0 (0)
 no 165 (97.6) 194 (100) 91 (100)
previous balloon microcompression 0.982
 yes 21 (12.4) 25 (12.9) 12 (13.2)
 no 148 (87.6) 169 (87.1) 79 (86.8)
previous microvascular decompression 0.999
 yes 13 (7.7) 15 (7.7) 7 (7.7)
 no 156 (92.3) 179 (92.3) 84 (92.3)
previous glycerol injection 1
 yes 1 (0.6) 2 (1) 0 (0)
 no 168 (99.4) 192 (99) 91 (100)
previous contralateral GKS 0.08
 yes 0 (0) 5 (2.6) 1 (1.1)
 no 169 (100) 189 (97.4) 90 (98.9)
TABLE 4: Preoperative hypesthesia in the 3 patient groups
No. of Patients (%)
Preop Hypesthesia
Group 1 
(169 
patients)
Group 2 
(194 
patients)
Group 3 
(91 
patients)
p 
Value
no hypesthesia 131 (77.5) 158 (81.4) 72 (79.1)
slight hypesthesia 34 (20.1) 33 (17) 18 (19.8) 0.874
severe hypesthesia 4 (2.4) 3 (1.5) 1 (1.1)
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Kondziolka et al.12 irradiated 2 male baboons (Pap-
io cynocephalus anubis) using doses of 80 and 100 Gy. 
Light and electron microscopic examinations were per-
formed to analyze specimens of the trigeminal nerve 6 
months after the procedure. The authors discovered acute 
degenerating axons with some identifiable myelinated ax-
ons, small foci of necrosis (including Schwann cell nu-
clei necrosis), and normal trigeminal ganglion when they 
used 80 Gy. At 100-Gy doses they found axon degenera-
tion with myelin vacuolation and expansion of the endo-
neurial intracellular matrix, which was consistent with 
edema. In one specimen, almost the entire width of the 
nerve was necrotic. Axon degeneration was noted outside 
the necrotic zone, but the histological features normal-
ized toward the ganglion. The authors concluded that the 
histological effects were dose related and consisted of 
primary axon injuries. They also observed no evidence 
of inflammation 6 months after GKS, and the extent of 
nerve edema was mild. Kondziolka et al. presumed that 
acute inflammation likely occurs after nerve irradiation 
(perhaps within the first few days) and may have effects 
on pathophysiological nerve processes, relieving pain 
quickly.
Szeifert et al.26 studied the histopathological findings 
in a patient who suffered from TN and was treated 2 times 
by GKS (in the first procedure, the maximum dose was 
90 Gy; in the second procedure, performed 10 months 
later, the maximum dose was 70 Gy). The patient died of 
a hemorrhagic stroke 26 days following the second inter-
vention, and an autopsy was performed. Histopathologi-
cal studies demonstrated changes in the trigeminal nerve 
that differed according to the sites of each treatment dose. 
Chronic radiation-induced changes were identified 11 
months after the first treatment, at the site treated with 
90 Gy: there was a well-circumscribed, hypocellular fi-
brotic lesion with hyaline-degenerated collagen bundles 
and scattered fibrocytes. Acute radiation-induced chang-
es, indicative of the early consequences of radiosurgery, 
were identified 26 days after the second treatment, at the 
site treated with 70 Gy: there was a sharply demarcated 
necrotic center containing fibrinoid material and tissue 
debris, which was encircled by surviving nerve bundles.
Conclusions
Our study was rather empirical (but also based on 
a statistical chart of distribution) in classifying the dis-
tribution of pain-free patients into the 3 subtypes. Our 
data indicate that pathophysiological mechanisms simi-
lar to those described in the other cited studies could 
be involved, but also some new ones—unknown for the 
moment—that could help explain the different patterns 
of freedom-from-pain responses after GKS. A substan-
tial number of patients, 169 (37.2%), became pain free 
within the first 48 hours (Group PF≤ 48 hours) after GKS; 
this is quite a large population. These patients had the 
lowest rate of hypesthesia in our series (13.7%), particu-
TABLE 5: Hypesthesia after GKS
No. of Patients (%)
Variable
Group 1 
(169 patients)
Group 2 
(194 patients)
Group 3 
(91 patients) p Value
hypesthesia after GKS 0.014
 yes 18 (13.7) 30 (19) 22 (30.5)
 no 113 (86.3) 128 (81) 50 (69)
type of hypesthesia 0.823
 discrete 13 (72.2) 21 (70) 14 (63.6)
 important 5 (27.8) 9 (30) 8 (36.4)
BNI type of hypesthesia 0.598
 mild facial numbness 15 (83.3) 27 (90) 18 (81.8)
 facial numbness, somewhat bothersome 2 (11.1) 3 (10) 3 (13.6)
 facial numbness, very bothersome 1 (5.6) 0 (0) 1 (4.6)
Fig. 2. Post-GKS hypesthesia in the 3 pain-free patient subgroups: 
Group PF≤ 48 hours, Group PF(> 48 hours, ≤ 30 days), and Group PF> 30 days. 
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larly compared with patients in the Group PF> 30 days, in 
which hypesthesia developed in 22 patients (30.6%) (data 
statistically significant, p = 0.014). The pain recurrence 
rate was 39% in Group PF≤ 48 hours, compared with 26.6% 
in Group PF(> 48 hours, ≤ 30 days) and 29.7% in Group PF> 30 days, 
but these data were not statistically significant (p = 0.515).
Given that targeting a small volume of normal tissue 
with a high radiation dose probably does not produce a 
destructive effect, the neuromodulatory mechanisms of 
GKS still need to be further analyzed and understood.
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TABLE 6: Management of pain recurrence with number and type of further surgical interventions
No. of Patients (%)
Variable
Group 1 
(169 patients)
Group 2 
(194 patients)
Group 3 
(91 patients) p Value
surgical treatment after GKS 0.619
 yes 33 (19.5) 39 (20.1) 14 (15.4)
 no 136 (80.5) 155 (79.9) 77 (84.6)
no. of surgeries after GKS 0.477
  1 26 (78.8) 28 (71.8) 8 (57.1)
  2 6 (18.2) 9 (23.1) 4 (28.6)
 ≥3 1 (3) 2 (5.1) 2 (14.3)
further thermocoagulation 0.849
 yes 10 (30.3) 10 (25.6) 3 (21.4)
 no 23 (69.7) 29 (74.4) 11 (78.6)
further balloon microcompression 0.873
 yes 19 (57.6) 22 (56.4) 9 (64.3)
 no 14 (42.4) 17 (43.6) 5 (35.7)
further microvascular decompression 0.602
 yes 4 (12.1) 8 (20.5) 3 (21.4)
 no 29 (87.9) 31 (79.5) 11 (78.6)
further cortical stimulation 1
 yes 0 (0) 1 (2.6) 0 (0)
 no 33 (100) 38 (97.4) 14 (100)
TABLE 7: Outcome at the last follow-up based on BNI 
classification
No. of Patients (%)
Variable
Group 1 
(169 
patients)
Group 2 
(194 
patients)
Group 3 
(91 
patients)
p 
Value
BNI classification 0.874
 good outcome 165 (97.6) 188 (96.9) 88 (96.7)
 poor outcome 4 (2.4) 6 (3.1) 3 (3.3)
Fig. 3. Probability of maintaining pain relief in the 3 pain-free pa- 
tient subgroups: Group PF≤ 48 hours, Group PF(> 48 hours, ≤ 30 days), and Group 
PF> 30 days. 
C. Tuleasca et al.
188                                                                                                                      J Neurosurg / Volume 117 / December 2012
support: Tuleasca, Donnet, Roussel, Levivier, Régis. Study supervi-
sion: Donnet, Roussel, Gaudart, Levivier, Régis.
References
 1. Brisman R: Gamma knife radiosurgery for primary manage-
ment for trigeminal neuralgia. J Neurosurg 93 (Suppl 3): 
159–161, 2000
 2. Brisman R, Mooij R: Gamma knife radiosurgery for trigemi-
nal neuralgia: dose-volume histograms of the brainstem and 
trigeminal nerve. J Neurosurg 93 (Suppl 3):155–158, 2000
 3. Flickinger JC, Pollock BE, Kondziolka D, Phuong LK, Foote 
RL, Stafford SL, et al: Does increased nerve length within the 
treatment volume improve trigeminal neuralgia radiosurgery? 
A prospective double-blind, randomized study. Int J Radiat 
Oncol Biol Phys 51:449–454, 2001
 4. Fountas KN, Lee GP, Smith JR: Outcome of patients undergo-
ing gamma knife stereotactic radiosurgery for medically re-
fractory idiopathic trigeminal neuralgia: Medical College of 
Georgia’s experience. Stereotact Funct Neurosurg 84:88–
96, 2006
 5. Fujimaki T, Hoya K, Sasaki T, Kirino T: Recurrent trigemi-
nal neuralgia caused by an inserted prosthesis: report of two 
cases. Acta Neurochir (Wien) 138:1307–1310, 1996
 6. Han JH, Kim DG, Chung HT, Paek SH, Kim YH, Kim CY, et 
al: Long-term outcome of gamma knife radiosurgery for treat-
ment of typical trigeminal neuralgia. Int J Radiat Oncol Biol 
Phys 75:822–827, 2009
 7. Headache Classification Subcommitee of the International 
Headache Society: The International Classification of Head-
ache Disorders: 2nd edition. Cephalalgia 24 Suppl 1:9–160, 
2004
 8. Hilton DA, Love S, Gradidge T, Coakham HB: Pathological 
findings associated with trigeminal neuralgia caused by vas-
cular compression. Neurosurgery 35:299–303, 1994
 9. Jannetta PJ: Neurovascular compression in cranial nerve and 
systemic disease. Ann Surg 192:518–525, 1980
10. Knafo H, Kenny B, Mathieu D: Trigeminal neuralgia: out-
comes after gamma knife radiosurgery. Can J Neurol Sci 36: 
78–82, 2009
11. Knuckey NW, Gubbay SS: Familial trigeminal and glossopha-
ryngeal neuralgia. Clin Exp Neurol 16:315–319, 1979
12. Kondziolka D, Lacomis D, Niranjan A, Mori Y, Maesawa S, 
Fellows W, et al: Histological effects of trigeminal nerve ra-
diosurgery in a primate model: implications for trigeminal 
neuralgia radiosurgery. Neurosurgery 46:971–977, 2000
13. Kondziolka D, Zorro O, Lobato-Polo J, Kano H, Flannery TJ, 
Flickinger JC, et al: Gamma Knife stereotactic radiosurgery 
for idiopathic trigeminal neuralgia. Clinical article. J Neuro-
surg 112:758–765, 2010
14. Leksell L: Sterotaxic radiosurgery in trigeminal neuralgia. 
Acta Chir Scand 137:311–314, 1971
15. Love S, Coakham HB: Trigeminal neuralgia: pathology and 
pathogenesis. Brain 124:2347–2360, 2001
16. Lunsford LD, Young RF: Radiosurgery for trigeminal neural-
gia. Surg Neurol 54:285–287, 2000
17. Massager N, Lorenzoni J, Devriendt D, Desmedt F, Brotchi J, 
Levivier M: Gamma knife surgery for idiopathic trigeminal 
neuralgia performed using a far-anterior cisternal target and a 
high dose of radiation. J Neurosurg 100:597–605, 2004
18. Massager N, Lorenzoni J, Devriendt D, Levivier M: Radiosur-
gery for trigeminal neuralgia. Prog Neurol Surg 20:235–243, 
2007
19. Pollock BE, Phuong LK, Gorman DA, Foote RL, Stafford SL: 
Stereotactic radiosurgery for idiopathic trigeminal neuralgia. 
J Neurosurg 97:347–353, 2002
20. Régis J, Arkha Y, Yomo S, Murata N, Roussel P, Donnet A, et 
al: [Radiosurgery in trigeminal neuralgia: long-term results 
and influence of operative nuances.] Neurochirurgie 55:213–
222, 2009 (Fr)
21. Régis J, Metellus P, Hayashi M, Roussel P, Donnet A, Bille-
Turc F: Prospective controlled trial of gamma knife surgery 
for essential trigeminal neuralgia. J Neurosurg 104:913–924, 
2006
22. Régis J, Tuleasca C: Fifteen years of Gamma Knife surgery 
for trigeminal neuralgia in the Journal of Neurosurgery: his-
tory of a revolution in functional neurosurgery. Editorial. J 
Neurosurg 115 Suppl:2–7, 2011
23. Reilly MM, Valentine AR, Ginsberg L: Trigeminal neuralgia 
associated with osteogenesis imperfecta. J Neurol Neuro-
surg Psychiatry 58:665, 1995
24. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser 
BL: Gamma knife radiosurgery for trigeminal neuralgia: the 
initial experience of The Barrow Neurological Institute. Int J 
Radiat Oncol Biol Phys 47:1013–1019, 2000
25. Ruelle A, Datti R, Andrioli G: Cerebellopontine angle osteo-
ma causing trigeminal neuralgia: case report. Neurosurgery 
35:1135–1137, 1994
26. Szeifert GT, Salmon I, Lorenzoni J, Massager N, Levivier M: 
Pathological findings following trigeminal neuralgia radiosur-
gery. Prog Neurol Surg 20:244–248, 2007
27. Zhao ZF, Yang LZ, Jiang CL, Zheng YR, Zhang JW: Gamma 
Knife irradiation-induced histopathological changes in the 
trigeminal nerves of rhesus monkeys. Laboratory investiga-
tion. J Neurosurg 113:39–44, 2010
Manuscript submitted May 19, 2012.
Accepted August 1, 2012.
Portions of this study were presented in abstract form at the 16th 
International Meeting of the Leksell Gamma Knife Society, Sydney, 
Australia, March 2012.
Please include this information when citing this paper: DOI: 
10.3171/2012.8.GKS121015.
Address correspondence to: Constantin Tuleasca, M.D., Centre 
Hos pitalier Universitaire Vaudois, Neurosurgery Service and 
Gamma Knife Center, Rue de Bugnon 44-46, BH-08, CH-1011 
Lausanne, Switzerland. email: constantin.tuleasca@gmail.com.
